RemeGen CoFRA:REG -2.42%39 PS Ratio is 19.95 as of Jul. 11, 2026, which is 21% above its 10-year median of 16.49. GuruFocus rates FRA:REG with a GF Score™ of 39/100 and a GF Value™ of €15.26 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, RemeGen Co ranks worse than 64.3% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, RemeGen Co's share price is €9.358.
RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.47. Hence, RemeGen Co's PS Ratio for today is 19.95.
Good Sign:
RemeGen Co Ltd stock PS Ratio (=12.91) is close to 1-year low of 12.91.
The historical rank and industry rank for RemeGen Co's PS Ratio or its related term are showing as below:
FRA:REG'
s PS Ratio Range Over the Past 10 Years
Min: 3.41 Med: 16.49 Max: 64.78
Current: 19.19
During the past 8 years, RemeGen Co's highest PS Ratio was 64.78. The lowest was 3.41. And the median was 16.49.
FRA:REG's PS Ratio is ranked worse than 64.3% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs FRA:REG: 19.19
During the past 12 months, the average Revenue per Share Growth Rate of RemeGen Co was 91.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 59.20% per year.
During the past 8 years, RemeGen Co's highest 3-Year average Revenue per Share Growth Rate was 409.80% per year. The lowest was -1.70% per year. And the median was 59.20% per year.
Back to Basics: PS Ratio
RemeGen Co (FRA:REG) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
RemeGen Co PS Ratio Related Terms
RemeGen Co PS Ratio Historical Data
* Premium members only.
The historical data trend for RemeGen Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RemeGen Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where RemeGen Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
RemeGen Co's Share Price of today is €9.358. RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
RemeGen Co (FRA:REG) has a PS Ratio of 19.95 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on RemeGen Co and its competitors. This is 21% above median its historical median of 16.49. Over the past decade, RemeGen Co's PS Ratio has ranged from 3.41 to 64.78. According to the industry distribution chart, RemeGen Co ranks #598 out of 930 companies in the Biotechnology industry, placing it in the top 64.3%.
Is RemeGen Co's PS Ratio too high?
RemeGen Co's current PS Ratio of 19.95 is 21% above median its 10-year median of 16.49. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 64.78. The Biotechnology industry median PS Ratio is 9.52. RemeGen Co's value of 19.95 is 109.7% above this industry median. Based on the distribution chart, RemeGen Co ranks #598 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #598 out of 930 companies for PS Ratio. This places RemeGen Co in the lower half of its industry. The industry median PS Ratio is 9.52. RemeGen Co's value of 19.95 is 109.7% above this benchmark. Historically, RemeGen Co's own PS Ratio has ranged from 3.41 to 64.78 over the past decade. While the company's 10-year median is 16.49 vs. the industry median of 9.52, RemeGen Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current PS Ratio of 19.95 is 109.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current PS Ratio is 19.95, which is 21% above median its own 10-year median of 16.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €15.26, compared to a current price of €9.36 — trading 38.7% below its estimated fair value. The current PS Ratio is 19.95, which is 21% above median its 10-year median of 16.49 and 109.7% above the Biotechnology industry median of 9.52. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current PS Ratio is 19.95 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.36 is trading 38.7% below its estimated GF Value™ of €15.26.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
PS Ratio: 19.95 (21% above median its 10-year median of 16.49)
GF Value™: €15.26 vs. price of €9.36 (38.7% below fair value)
Industry Position: 109.7% above the Biotechnology median (#598 of 930)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score
Get the complete analysis for FRA:REG
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
